Leading diabetes nurse consultant and co-founder of Trend Diabetes, Debbie Hicks, has joined medtech start-up Gendius to advise on the further development of its remote diabetes management technology platforms.
Gendius is developing a range of remote management platforms for diabetes, including Intellin®, which is now the world’s fastest-growing diabetes management app with more than 230,000 downloads worldwide. Unlike many other diabetes tracking apps, Intellin® highlights users’ risk profiles, to help users to plan for the future, and reduce their risk of developing complications.
Debbie comments, "I am delighted to join Gendius' Advisory Board. They have many exciting plans within diabetes care and for people with diabetes, both in the UK and farther afield, which I look forward to being a part of. I have been remotely managing people with diabetes for a very long time, and this has obviously increased hugely in the past three months due to Covid-19. It is increasingly clear that people need to be able to access information and advice when it suits them, and advances in technology are now making this possible. I fully subscribe to what Gendius is trying to achieve, and I look forward to their future progress."
Debbie has worked in diabetes nursing since 1990, and is currently Nurse Consultant – Diabetes at Medicus Health Partners, working to improve diabetes care delivery across a group of 15 GP practices in Enfield. Debbie is also the founding member and Co-Chair of Trend Diabetes (Training, Research and Education for Nurses in Diabetes). She was Editor-in-Chief of the Journal of Diabetes Nursing from 2007 to 2017, and is currently an editorial board member of The Diabetes Times.
Debbie was the First Chair and founder of Forum for Injection Technique UK (FIT-UK), and is now Chair of Injection Technique Matters (ITM) – Best Practice in Diabetes Care. ITM aims to encourage best practice in injection technique for all healthcare professionals and people living with diabetes using injectable therapies, to ensure optimum benefit from these medications. Debbie won two National awards for her work on injection safety in 2013.
In addition, Debbie has published over a hundred and forty papers in the UK, Italy, France and the United States, with seventy as first author, since she began in diabetes nursing in 1990.
Gendius CEO, Rory Cameron, comments, “We are delighted that Debbie has agreed to join our advisory board. Her vast experience and knowledge of diabetes care will be invaluable to us and the future development of our remote diabetes management platforms. Diabetes nursing is an incredibly important part of diabetes care, and so it was especially important for us to make sure that it was represented in our advisory team.”
Gendius has recently announced a partnership with AstraZeneca to develop its diabetes management technology to support patients and healthcare professionals in Gulf Cooperation Council (GCC) countries. In addition to the continued development and improvement of the Intellin® platform, Gendius is also developing platforms to support young adults with diabetes, as well as those with gestational diabetes.
Gendius is a healthcare technology company based in Greater Manchester. It has developed a platform called Intellin®, which uses an algorithm to help diabetes patients to understand their risk of complications and how to manage them.